A carregar...
Scientific rationale for the possible inhaled corticosteroid intraclass difference in the risk of pneumonia in COPD
Inhaled corticosteroids (ICSs) treatment combined with long-acting β(2)-adrenoceptor agonists (LABAs) reduces the risk of exacerbations in COPD, but the use of ICSs is associated with increased incidence of pneumonia. There are indications that this association is stronger for fluticasone propionate...
Na minha lista:
| Publicado no: | Int J Chron Obstruct Pulmon Dis |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5654780/ https://ncbi.nlm.nih.gov/pubmed/29089754 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S143656 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|